Abstract
As a new faculty member at The Johns Hopkins University, School of Medicine, the author began research on cancer in 1969 because this frequently fatal disease touched many whom he knew. He was intrigued with its viscous nature, the failure of all who studied it to find a cure, and also fascinated by the pioneering work of Otto Warburg, a biochemical legend and Nobel laureate. Warburg who died 1 year later in 1970 had shown in the 1920s that the most striking biochemical phenotype of cancers is their aberrant energy metabolism. Unlike normal tissues that derive most of their energy (ATP) by metabolizing the sugar glucose to carbon dioxide and water, a process that involves oxygen-dependent organelles called “mitochondria”, Warburg showed that cancers frequently rely less on mitochondria and obtain as much as 50% of their ATP by metabolizing glucose directly to lactic acid, even in the presence of oxygen. This frequent phenotype of cancers became known as the “Warburg effect”, and the author of this review strongly believed its understanding would facilitate the discovery of a cure. Following in the final footsteps of Warburg and caught in the midst of an unpleasant anti-Warburg, anti-metabolic era, the author and his students/collaborators began quietly to identify the key molecular events involved in the “Warburg effect”. Here, the author describes via a series of sequential discoveries touching five decades how despite some impairment in the respiratory capacity of malignant tumors, that hexokinase 2 (HK-2), its mitochondrial receptor (VDAC), and the gene that encodes HK-2 (HK-2 gene) play the most pivotal and direct roles in the “Warburg effect”. They discovered also that like a “Trojan horse” the simple lactic acid analog 3-bromopyruvate selectively enters the cells of cancerous animal tumors that exhibit the “Warburg effect” and quickly dissipates their energy (ATP) production factories (i.e., glycolysis and mitochondria) resulting in tumor destruction without harm to the animals.
References
Ahmed FE (2007) J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 25:101–154
Altenberg B, Greulich KO (2004) Genomics 84:1014–1020
Arora KK, Pedersen PL (1988) J Biol Chem 263:17422–17428
Arora KK, Fanciulli M, Pederson PL (1990) J Biol Chem 265:6481–6488
Arora KK, Filburn CR, Pederson PL (1991) J Biol Chem 266:5359–5362
Arora KK, Filburn CR, Pederson PL (1993) J Biol Chem 268:18259–18266
Azoulay-Zohar H, Israelson A, Abu-Hamad S, Shoshan-Barmatz V (2004) Biochem J 377(Pt 2):347–355
Bennett WS Jr., Steitz TA (1980) J Mol Biol 140:183–209
Birnbaum MJ (2004) Dev Cell 7:781–782
Bustamante E, Pedersen PL (1977) Proc Natl Acad Sci USA 74:3735–3739
Bustamante E, Morris HP, Pedersen PL (1981) J Biol Chem 256:8699–8704
Burk D, Woods M, Hunter J (1967) J Natl Cancer Inst 38:839–863
Chan TL, Greenawalt, JW, Pedersen PL (1970) J Cell Biol 45:291–305
Chen C, Ko YH, Delannoy M, Ludtke SJ, Chiu W, Pedersen PL (2004) 279:31761–31768
Chen C, Saxena AK, Simcoke WN, Garboczi DN, Pedersen PL, Ko YH (2006) J Biol Chem 281:13777–13783
Colombini M (1979) Nature 279:643–645
Devlin TM (2006) Textbook of Biochemistry with Clinical Correlations (6th edition): Chapter 15: Harris RA Carbohydrate Metabolism I: Major metabolic pathways and their controls pp 582–608
Di Chiro G, DeLaPaz RL, Brooks RA, Sokoloff L, Kornblith PL, Smith BH, Patronas NJ, Kufta CV, Kessler RM, Johnston GS, Manning RG, Wolf AP (1982) Neurology 32:1323–1329
Emboli ML, Paradies G, Galeotti T, Papa S (1977) Biochim Biophys Acta 460:183–187
Galluzzi L, Larochette N, Zamazami N, Kroemer G (2006) Oncogene 25:4812–4830
Geschwind JF, Ko YH, Torbenson MS, Magee C, Pedersen PL (2002) Cancer Res 62:3909–3913
Goel A, Mathupala SP, Pedersen PL (2003) J Biol Chem 278:15333–15340
Hammerman PS, Fox CJ, Thompson, CB (2004) Trends Biochem Sci 29:586–592
Herceg Z (2007) Mutagenesis 22:91–103
Indo T, Wan CN, Casella V et al (1978) J Label Compds Radiopharm 24:174–183
Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY, Cheson BD, O’shaughnessy J, Guyton KZ, Mankoff DA, Shankar L, Larson SM, Sigman CC, Schilsky RL, Sullivan DC (2005) Clin Cancer Res 11:2785–2808
Kim JW, Dang CV (2006) Cancer Res 66:8927–8930
Ko YH, McFadden BA (1990) Arch Biochem Biophys 278:373–380
Ko YH, Pedersen PL, Geschwind JF (2001) Cancer Lett 173:83–91
Ko YH, Delannoy M, Hullihen J, Chiu W, Pedersen PL (2003) J Biol Chem 278:12305–12309
Ko YH, Smith BL, Wang Y, Pomper MG, Rini DA, Torbenson MS, Hullihen J, Pedersen PL (2004) Biochem Biophys Res Commun 324:269–275
Lee MG, Pedersen PL (2003) J Biol Chem 278:41047–41058
Lemasters JJ, Holmuhamedov E (2006) Biochim Biophys Acta 1762:181–190
Linden M, Gellerfors P, Nelson BD (1982) FEBS Lett 141:189–192
Lo CH, Farina F, Morris HP, Weinhouse S (1968) Adv Enzyme Regul 6:453–464
Mathupala SP, Pedersen PL (1999) Proc Amer Assoc Cancer Res (Philadelphia, PA) Abs. #145, 22
Mathupala SP, Rempel A, Pedersen PL (1995) J Biol Chem 270:16918–16925
Mathupala SP, Heese C, Pedersen PL (1997) J Biol Chem 272:22776–22780
Mathupala SP, Rempel A, Pedersen PL (2001) J Biol Chem 276:43407–43412
Mathupala SP, Ko YH, Pedersen PL (2006) Oncogene 25:4777–4786
Majewski N, Nogueira V, Bhaskar P, Coy PE, Skeen JE, Gottlob K, Chandel NS, Thompson CB, Hay N (2004a) Mol Cell 16:819–830
Majewski N, Nogueira V, Robey RB, Hay N (2004b) Mol Cell Biol 24:730–740
Merida I, Avila-Flores A (2006) Clin Transl Oncol 8:711–716
Modica-Napolitano JS, Kulawiec M, Singh KK (2007) Curr Mol Med 7:121–131
Morris HP (1965) Adv Cancer Res 9:227–302
Nakashima RA, Mangan PS, Colombini M, Pedersen PL (1986) Biochemistry 25:1015–10121
Nakashima RA, Paggi MC, Scott LJ, Pedersen PL (1988) Cancer Res 48:913–919
Nelson BD, Kabir F, Muchiri P (1984) Biochem J 219:159–164
Pedersen PL (1978) Prog Exp Tumor Res 22:190–274
Pedersen PL (2007) J Bioenerg Biomemb 39:1–12
Pedersen PL, Greenawalt JW, Chan TL, Morris HP (1970) Cancer Res 30:2620–2626
Pedersen PL, Mathupala S, Rempel A, Geschwind JF, Ko YH (2002) Biochem Biophys Acta 1555:14–20
Parry D, Pedersen PL (1983) J Biol Chem 258:10904–10912
Pastorino JG, Hoek JB (2003) Curr Med Chem 10:1535–1551
Pastorino JG, Shulga N, Hoek JB (2002) J Biol Chem 277:7610–7618
Pauser S, Wagner S, Lippmann M, Pohlen U, Reszka R, Wolf KJ, Berger G (1996) Cancer Res 56:1863–1867
Phelps ME (2000) Proc Natl Acad Sci 97:9226–9233
Phelps ME, Hoffman EF, Mullani NA, Ter-Pogossian MM (1975) In: Deblanc H, Sorenson JA (eds) Non-invasive brain imaging, radionuclides and computed tomography. New York: Soc Nucl Med 87–109 Rose IA, Warms JV (1967) J Biol Chem 242:1635–1645
Rempel A, Mathupala SP, Griffin CA, Hawkins AL, Pedersen PL (1996) Cancer Res 56:2468–2471
Ristow M (2006) Curr Opin Clin Nutr Metab Care 9:339–345
Robey RB, Hay N (2005) Cell Cycle 4:654–658
Robey RB, Hay N (2006) Oncogene 25:4683–4696
Rose IA, Warms JV (1967) J Biol Chem 242:1635–1645
Rostovtseva TK, Tan W, Colombini M (2005) J Bioenerg Biomemb 37:129–142
Schnaitman C, Greenawalt JW (1968) J Cell Biol 38:158–175
Schreiber JR, Balcavage WX, Morris HP, Pedersen PL (1970) Cancer Res 30:2497–2501
Smith DF, Walborg EF Jr, Chang JP (1970) Cancer Res 30:2306–2309
Vander Heiden MG, Plas DR, Rathmell JC, Fox CJ, Harris MH, Thompson CB (2001) Mol Cell Bio 21:5899–5912
Wallace DC (2005) Cold Spring Harb Symp Quant Biol 70:363–374
Warburg O (1930) The metabolism of tumours. London Constable Co Ltd, 1930
Warburg O (1956) Science 124:269–270
Weber G, Lea MA (1966) Adv Enzyme Regul 4:115–145
Zaid H, Abu-Hamad S, Israelson A, Nathan I, Shoshan-Barmatz V (2005) Cell Death Differ 12:751–760
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pedersen, P.L. Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers’ most common phenotypes, the “Warburg Effect”, i.e., elevated glycolysis in the presence of oxygen. J Bioenerg Biomembr 39, 211–222 (2007). https://doi.org/10.1007/s10863-007-9094-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10863-007-9094-x